STENOTROPHOMONAS MALTOPHILIA LUMBAR SPONDYLODISCITIS IN A CKD PATIENT

Dr Abhishek Kumar, Dr Mandar Borde, Dr Akash Mane, Dr. Tanmay Datey, Dr K.V. Menon

Abstract


Stenotrophomonas maltophilia is an increasingly recognized cause of severe nosocomial infections, particularly in immunocompromised individuals. Community-acquired infections have also been reported. We present a case of lumbar spondylodiscitis caused by S. maltophilia in a chronic kidney disease (CKD) patient undergoing maintenance hemodialysis. This report highlights the diagnostic challenges and management of such infections in an immunocompromised host. The discussion also elaborates on the pathogen’s biofilm-forming capabilities, antimicrobial resistance, and the importance of multidisciplinary management in achieving favorable outcomes. 


Keywords


Spondylodiscitis, Stenotrophomonas maltophilia, Chronic Kidney Disease, Hemodialysis, Nosocomial Infections

Full Text:

PDF

References


Brooke, J.S. Advances in the microbiology of Stenotrophomonas maltophilia. Clin Microbiol Rev. 2021;34(3).

Looney, W.J., Narita, M., Mühlemann, K. Stenotrophomonas maltophilia: An emerging opportunist human pathogen. Lancet Infect Dis. 2009;9:312–323.

Adegoke, A.A., Stenstrom, T.A., Okoh, A.I. Stenotrophomonas maltophilia as an emerging ubiquitous pathogen: Looking beyond contemporary antibiotic therapy. Front Microbiol. 2017;8:2276.

Falagas, M.E., Kastoris, A.C., Vouloumanou, E.K., Rafailidis, P.I. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: A systematic review. J Antimicrob Chemother. 2009;64(5):889–894.

Maria F. Mojica, Romney Humphries, John J. Lipuma, Amy J. Mathers, Gauri G. Rao, Samuel A. Shelburne, Derrick E. Fouts, David Van Duin, Robert A. Bonomo, Clinical challenges treating Stenotrophomonas maltophilia infections: an update, JAC-Antimicrobial Resistance, Volume 4, Issue 3, June 2022, dlac040.

Kuwahara M, Noma M, Sunakawa T, Shirai K, Kohama K, Miyawaki A, Hirata JI. Stenotrophomonas maltophilia Bacteremia Associated With Severe COVID-19: Successful Treatment With Appropriate Antimicrobial Therapy. Cureus. 2022 Jan 30;14(1):e21750.

Di Bonaventura G, Spedicato I, D'Antonio D, Robuffo I, Piccolomini R. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother. 2004 Jan;48(1):151-60.

García, G., Girón, J. A., Yañez, J. A., & Cedillo, M. L. (2022). Stenotrophomonas maltophilia and Its Ability to Form Biofilms. Microbiology Research, 14(1), 1–20.

Wang, A., Wang, Q., Kudinha, T. et al. Effects of Fluoroquinolones and Azithromycin on Biofilm Formation of Stenotrophomonas maltophilia. Sci Rep 6, 29701 (2016).

Wu, J., He, S., Guo, S., et al. The role of biofilms in Stenotrophomonas maltophilia infections and their potential therapeutic strategies. Front Cell Infect Microbiol. 2020;10:561324.


Refbacks

  • There are currently no refbacks.